Log in to your Inderes Free account to see all free content on this page.
SynAct Pharma
17.42 SEK
-0.57 %
Less than 1K followers
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for SynAct Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -23.7 | -31.0 | -76.7 | -105.7 | -224.5 | -90.0 | - |
| EBIT | -24.1 | -31.3 | -76.7 | -105.7 | -224.5 | -90.0 | -116.5 |
| Profit before taxes | -27.1 | -31.3 | -76.8 | -107.1 | -224.3 | -90.8 | -119.0 |
| Net income | -24.0 | -26.6 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 |
| EPS | -1.61 | -1.07 | -2.64 | -3.57 | -6.58 | -2.08 | -2.17 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -177.4 % | -167.3 % | -332.1 % | -78.4 % | -122.5 % | -38.5 % | -65.1 % |
| ROI | -100.6 % | -123.0 % | -180.6 % | -69.6 % | -94.6 % | -30.5 % | -50.3 % |
Login required
This content is only available for logged in users